Truist Securities analyst Danielle Brill reiterated a Hold rating and $189.00 price target on Biogen (NASDAQ: BIIB).The analyst commented: "BIIB080 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments